Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PP-F11N in Metastatic Medullary Thyroid Cancer
NCT02088645Phase 1Active, not recruiting
- Sponsor
- University Hospital Basel
- Start
- Apr 2015
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-PP-F11N in Medullary Thyroid Cancer (MTC) and Neuroendocrine Neoplasm (NEN), sponsored by University Hospital Basel. Primary endpoints: Scintigraphic visualisation rate at 4 weeks and Maximum tolerated dose at 9 months. Started Apr 2015; status: active, not recruiting.
02
Drugs
177Lu-PP-F11N
03
Conditions
Medullary Thyroid Cancer (MTC)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT02088645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02088645.